cisplatin + cyclophosphamide + epirubicin + paclitaxel + vinblastine

This is a multi-agent chemotherapy regimen composed of five cytotoxic drugs: cisplatin, cyclophosphamide, epirubicin, paclitaxel, and vinblastine. Each component has a distinct mechanism of action targeting cancer cells at different stages of the cell cycle or through different cellular processes. Such combinations are used in oncology to maximize antitumor efficacy by attacking cancer cells via multiple pathways and to reduce the likelihood of drug resistance. This specific combination is not recognized as a standard named regimen but may be used in research or highly refractory cases where multiple mechanisms are desired. - **Cisplatin** is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function. - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication by adding alkyl groups to DNA. - **Epirubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II. - **Paclitaxel** stabilizes microtubules and prevents their depolymerization, disrupting mitosis. - **Vinblastine** binds tubulin and inhibits microtubule formation during cell division[2][4]. The combination targets rapidly dividing tumor cells through complementary mechanisms including direct DNA damage, inhibition of mitotic spindle formation, interference with topoisomerase activity, and disruption of microtubule dynamics.